Characteristics of the study participants, July—September 2016, South Africa.

<p>Characteristics of the study participants, July—September 2016, South Africa.</p

Preferred method of response to the survey among study participants, July—September 2016, South Africa (N = 459).

<p>Preferred method of response to the survey among study participants, July—September 2016, South Africa (N = 459).</p

Prevalence of TB among the study participants, July—September 2016, South Africa.

<p>Prevalence of TB among the study participants, July—September 2016, South Africa.</p

Characteristics of all TB patients and MDR-TB patients at the time of TB diagnosis.

<p>Abbreviations: LPA, MTBDR<i>plus</i> line probe assay, IQR, interquartile range; HIV, human immunodeficiency virus; ART, antiretroviral therapy; TB, tuberculosis.</p>*<p>p values are for comparison of the Before LPA period versus the After LPA period.</p>**<p>CD4 cell counts within 6 months of TB diagnosis were recorded for 502 (75%) during the Before LPA period and 612 (89%) during the After LPA period.</p

Drug resistance by study period.

<p>Abbreviations: LPA, Hain MTBDR<i>plus</i> line probe assay; CI, confidence interval; MDR, multi-drug resistant; INH, isoniazid; RIF, rifampin.</p>*<p>Any resistance refers to resistance to either INH or RIF, or both.</p

All-cause mortality by 8 months following initial registration among all MDR patients, by study period.

<p>Kaplan-Meir curves for time from initial TB case registration to death by all causes among all MDR patients, by study period<b>.</b> Abbreviation: LPA, MTBDR<i>plus</i> line probe assay.</p

Time to MDR treatment among MDR-TB patients, by study period.

<p>Kaplan-Meir curves for time from initial sputum collection to MDR treatment by study period, including a modeled Before LPA period where the number of MDR-TB cases during the Before LPA period was augmented to match that observed during the After LPA period. Abbreviations: LPA, MTBDR<i>plus</i> line probe assay; MDR, multidrug resistant tuberculosis.</p

DST by patient category and study period.

<p>A breakdown of whether DST was performed or not, by study period (Before and After LPA) and patient category (New versus Retreatment). Abbreviations: LPA, MTBDR<i>plus</i> line probe assay; DST, drug susceptibility testing.</p

DST algorithm by study period.

<p>An illustration of the DST algorithm in the Before LPA period (A) and the After LPA period (B). Abbreviations: DST, drug susceptibility testing; LPA, line probe assay; TB, tuberculosis; MDR-TB, multidrug resistant tuberculosis.</p

Time to treatment and drug susceptibility test turnaround times by study period.

<p>An illustration of critical events in the time to MDR treatment and DST turnaround. Abbreviations: DST, drug susceptibility testing; LPA, MTBDR<i>plus</i> line probe assay; MDR, multi-drug resistant tuberculosis; IQR, inter-quartile range.</p